<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849287</url>
  </required_header>
  <id_info>
    <org_study_id>170PK18039</org_study_id>
    <nct_id>NCT03849287</nct_id>
  </id_info>
  <brief_title>Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults</brief_title>
  <official_title>An Open-label, Randomized, Fasted, Single-dose, Three-way Crossover Study to Compare the Pharmacokinetic Characteristics and Safety Between Administration of CKD-333 and Coadministration of CKD-330 and D090 in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of clinical trial is to investigate the pharmacokinetics and safety compared to
      CKD-333 and co-administration CKD-330, D090 under fasting condition in healthy male adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, fasted, single-dose, three-way crossover study to compare the
      pharmacokinetic characteristics and safety between administration of CKD-333 and
      coadministration of CKD-330 and D090 in healthy male adults
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 25, 2019</start_date>
  <completion_date type="Anticipated">April 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of Candesartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of Amlodipine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve to last concentration of Atorvastatin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Candesartan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Amlodipine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Maximum plasma concentration of Atorvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of Candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of Amlodipine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of Atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of 2-hydroxy atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity concentration of 2-hydroxy atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of Candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of Amlodipine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of Atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of 2-hydroxy atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Time to maximum plasma concentration of 2-hydroxy atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Half-life of Candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Half-life of Amlodipine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Half-life of Atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of 2-hydroxy atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Half-life of 2-hydroxy atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent clearance of Candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent clearance of Amlodipine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent clearance of Atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance of 2-hydroxy atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent clearance of 2-hydroxy atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Candesartan</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Candesartan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Amlodipine</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Amlodipine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of Atorvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of 2-hydroxy atorvastatin</measure>
    <time_frame>0 hour ~ 72 hour after drug administration</time_frame>
    <description>Apparent volume of distribution of 2-hydroxy atorvastatin</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-333, formula I
Period 2: CKD-333, formula II
Period 3: CKD-330, D090</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-333, formula I
Period 2: CKD-330, D090
Period 3: CKD-333, formula II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-333, formula II
Period 2: CKD-330, D090
Period 3: CKD-333, formula I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-333, formula II
Period 2: CKD-333, formula I
Period 3: CKD-330, D090</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-330, D090
Period 2: CKD-333, formula I
Period 3: CKD-333, formula II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-330, D090
Period 2: CKD-333, formula II
Period 3: CKD-333, formula I</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-333, formula I</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-333, formula II</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330, D090</intervention_name>
    <description>Reference Drug</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male adults aged 19 to 45 years

          2. Body weight more than 50kg and within ideal body weight ±20%

          3. signed informed consent form

        Exclusion Criteria:

          1. Have clinical significant medical history or disease that cardiovascular system,
             respiratory system, kidney, endocrine system, hematological system, digestive system ,
             mental illness

          2. Have a gastrointestinal disease history that can effect drug absorption or surgery

          3. Systolic Blood pressure≥140mmHg or Systolic Blood pressure&lt;90mmHg, Diastolic Blood
             Pressure≥90mmHg or Diastolic Blood Pressure&lt;60mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seunghun Han, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Seoul ST.Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seunghun Han, Ph.D.</last_name>
    <phone>+82-2-2258-7326</phone>
    <email>waystolove@catholic.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Seunghun Han, Ph.D.</last_name>
      <phone>+82-2-2258-7326</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

